Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of olaparib maintenance after response to trabectedin + pegylated liposomal doxorubicin in recurrent ovarian carcinoma
2017-003183-13Phase 2Terminated
- Sponsor
- Grupo Español de Investigación en Cáncer de Ovario
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of olaparib in ovarian cancer, sponsored by Grupo Español de Investigación en Cáncer de Ovario. Primary endpoint: Progression free survival. Started Apr 2018; status: terminated.
02
Drugs
olaparib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2017-003183-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003183-13.